Fig. 5From: A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patientsResponse to treatment assessed for each patient on time to disease progression in weeks after 90Y-OTSA-101 injectionBack to article page